• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三阴性乳腺癌中受体 ER、PR 和 HER2 的缺失会促进 USP15 依赖性 PARP1 的稳定。

Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer.

机构信息

Shanghai Key Laboratory of Maternal Fetal Medicine, Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.

Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.

出版信息

Nat Cancer. 2023 May;4(5):716-733. doi: 10.1038/s43018-023-00535-w. Epub 2023 Apr 3.

DOI:10.1038/s43018-023-00535-w
PMID:37012401
Abstract

Poly(ADP-ribose) polymerase 1 (PARP1) is essential for the progression of several types of cancers. However, whether and how PARP1 is stabilized to promote genomic stability in triple-negative breast cancer (TNBC) remains unknown. Here, we demonstrated that the deubiquitinase USP15 interacts with and deubiquitinates PARP1 to promote its stability, thereby stimulating DNA repair, genomic stability and TNBC cell proliferation. Two PARP1 mutations found in individuals with breast cancer (E90K and S104R) enhanced the PARP1-USP15 interaction and suppressed PARP1 ubiquitination, thereby elevating the protein level of PARP1. Importantly, we found that estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) inhibited USP15-mediated PARP1 stabilization through different mechanisms. ER bound to the USP15 promoter to suppress its expression, PR suppressed the deubiquitinase activity of USP15, and HER2 abrogated the PARP1-USP15 interaction. The specific absence of these three receptors in TNBC results in high PARP1 levels, leading to increases in base excision repair and female TNBC cell survival.

摘要

聚(ADP-核糖)聚合酶 1(PARP1)对于几种类型的癌症的进展至关重要。然而,PARP1 是否以及如何稳定以促进三阴性乳腺癌(TNBC)中的基因组稳定性仍然未知。在这里,我们证明去泛素酶 USP15 与 PARP1 相互作用并去泛素化 PARP1 以促进其稳定性,从而刺激 DNA 修复、基因组稳定性和 TNBC 细胞增殖。在患有乳腺癌的个体中发现的两种 PARP1 突变(E90K 和 S104R)增强了 PARP1-USP15 相互作用并抑制了 PARP1 泛素化,从而提高了 PARP1 的蛋白水平。重要的是,我们发现雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体 2(HER2)通过不同的机制抑制 USP15 介导的 PARP1 稳定。ER 结合到 USP15 启动子上以抑制其表达,PR 抑制 USP15 的去泛素酶活性,而 HER2 破坏了 PARP1-USP15 相互作用。这些三种受体在 TNBC 中的特异性缺失导致 PARP1 水平升高,导致碱基切除修复增加和女性 TNBC 细胞存活增加。

相似文献

1
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer.三阴性乳腺癌中受体 ER、PR 和 HER2 的缺失会促进 USP15 依赖性 PARP1 的稳定。
Nat Cancer. 2023 May;4(5):716-733. doi: 10.1038/s43018-023-00535-w. Epub 2023 Apr 3.
2
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.雄激素受体阳性三阴性乳腺癌中PARP1与BRCA1的相关性
Int J Biol Sci. 2016 Nov 25;12(12):1500-1510. doi: 10.7150/ijbs.16176. eCollection 2016.
3
Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.化疗相对剂量强度对 I-III 期乳腺癌(ER+/PR+、HER2- 与三阴性)的特定病因和总生存的影响。
Breast Cancer Res Treat. 2018 May;169(1):175-187. doi: 10.1007/s10549-017-4646-1. Epub 2018 Jan 24.
4
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.猫乳腺基底样腺癌:一种具有基底样亚型的人类三阴性乳腺癌(TNBC)的潜在模型。
BMC Cancer. 2013 Sep 3;13:403. doi: 10.1186/1471-2407-13-403.
5
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.三阴性乳腺癌及其他原发性人类肿瘤类型中聚(ADP-核糖)聚合酶-1(PARP1)的上调
Genes Cancer. 2010 Aug;1(8):812-21. doi: 10.1177/1947601910383418.
6
Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.SIRT1、SIRT3 和 SIRT6 基因的表达对三阴性和激素受体阳性乳腺癌亚型生存的预测作用。
Pathol Oncol Res. 2020 Oct;26(4):2723-2731. doi: 10.1007/s12253-020-00873-5. Epub 2020 Jul 17.
7
Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin.雷公藤内酯醇干扰 XRCC1/PARP1 介导的 DNA 修复,增强三阴性乳腺癌细胞对顺铂的敏感性。
Biomed Pharmacother. 2019 Jan;109:1541-1546. doi: 10.1016/j.biopha.2018.11.008. Epub 2018 Nov 14.
8
Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.三阴性乳腺癌与聚(ADP-核糖)聚合酶抑制剂。
Anticancer Agents Med Chem. 2012 Jul;12(6):672-7. doi: 10.2174/187152012800617759.
9
PARP1 and PRC2 double deficiency promotes BRCA-proficient breast cancer growth by modification of the tumor microenvironment.PARP1 和 PRC2 双重缺失通过肿瘤微环境的改变促进了 BRCA 功能正常的乳腺癌生长。
FEBS J. 2021 May;288(9):2888-2910. doi: 10.1111/febs.15636. Epub 2020 Dec 2.
10
The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.雌激素阴性/孕激素阳性(ER-/PR+)表型的预后和预测价值:单中心 1159 例原发性乳腺癌的经验。
Breast J. 2022 May 17;2022:9238804. doi: 10.1155/2022/9238804. eCollection 2022.

引用本文的文献

1
PARP (Poly ADP-ribose Polymerase) Family in Health and Disease.健康与疾病中的PARP(聚ADP核糖聚合酶)家族
MedComm (2020). 2025 Sep 1;6(9):e70314. doi: 10.1002/mco2.70314. eCollection 2025 Sep.
2
Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer.Jab1调节HRR mRNA稳定性以调节三阴性乳腺癌中PARP抑制剂的敏感性。
Mol Cancer. 2025 Aug 16;24(1):217. doi: 10.1186/s12943-025-02422-7.
3
USP15 Drives NSCLC Progression and Chemoresistance, Potentially via Regulation of the U2-Type Spliceosomal Complex.

本文引用的文献

1
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.奥拉帕利单药作为未经选择的三阴性乳腺癌的一线治疗。
Ann Oncol. 2021 Feb;32(2):240-249. doi: 10.1016/j.annonc.2020.11.009. Epub 2020 Nov 24.
2
The SIRT6 activator MDL-800 improves genomic stability and pluripotency of old murine-derived iPS cells.SIRT6 激活剂 MDL-800 可提高老年鼠源性 iPS 细胞的基因组稳定性和多能性。
Aging Cell. 2020 Aug;19(8):e13185. doi: 10.1111/acel.13185. Epub 2020 Jul 21.
3
Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.
USP15可能通过调节U2型剪接体复合物驱动非小细胞肺癌进展和化疗耐药。
Cancer Med. 2025 Aug;14(15):e71055. doi: 10.1002/cam4.71055.
4
NASP Promotes Triple-negative Breast Cancer Progression and Metastasis by Stabilizing YAP in a USP15-Dependent Way.NASP通过以USP15依赖的方式稳定YAP来促进三阴性乳腺癌的进展和转移。
Int J Biol Sci. 2025 Jun 20;21(9):4172-4186. doi: 10.7150/ijbs.99438. eCollection 2025.
5
A 'two-missile' nanoplatform for targeting triple-negative breast cancer: prodrug activation and immune enhancement.一种用于靶向三阴性乳腺癌的“双导弹”纳米平台:前药激活与免疫增强
Mater Today Bio. 2025 May 20;32:101891. doi: 10.1016/j.mtbio.2025.101891. eCollection 2025 Jun.
6
USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment.USP15通过SMYD3/CCL2依赖的髓源性抑制细胞招募促进结直肠癌免疫逃逸。
Cancer Immunol Res. 2025 Aug 1;13(8):1226-1245. doi: 10.1158/2326-6066.CIR-24-1194.
7
The deubiquitination-PARylation positive feedback loop of the USP10-PARP1 axis promotes DNA damage repair and affects therapeutic efficacy of PARP1 inhibitor.USP10-PARP1轴的去泛素化-聚腺苷酸化正反馈环促进DNA损伤修复并影响PARP1抑制剂的治疗效果。
Oncogene. 2025 May 2. doi: 10.1038/s41388-025-03428-7.
8
Visualization analysis of breast cancer-related ubiquitination modifications over the past two decades.过去二十年乳腺癌相关泛素化修饰的可视化分析
Discov Oncol. 2025 Mar 31;16(1):431. doi: 10.1007/s12672-025-02032-1.
9
Bruceine A Inhibits Cell Proliferation by Targeting the USP13/PARP1 Signalling Pathway in Multiple Myeloma.鸦胆子素A通过靶向多发性骨髓瘤中的USP13/PARP1信号通路抑制细胞增殖。
Basic Clin Pharmacol Toxicol. 2025 Apr;136(5):e70027. doi: 10.1111/bcpt.70027.
10
p53 inhibits OTUD5 transcription to promote GPX4 degradation and induce ferroptosis in gastric cancer.p53抑制OTUD5转录以促进GPX4降解并诱导胃癌中的铁死亡。
Clin Transl Med. 2025 Mar;15(3):e70271. doi: 10.1002/ctm2.70271.
聚腺苷二磷酸核糖聚合酶 1(PARP1)和 DNA 依赖性蛋白激酶(DNA-PK)抑制剂联合用于肝细胞癌的合理治疗。
Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26356-26365. doi: 10.1073/pnas.2002917117. Epub 2020 Oct 5.
4
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.尼拉帕利联合卡铂和紫杉醇治疗 BRCA 突变型晚期乳腺癌(BROCADE3):一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2020 Oct;21(10):1269-1282. doi: 10.1016/S1470-2045(20)30447-2. Epub 2020 Aug 27.
5
The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.泛素连接酶 TRIP12 限制 PARP1 捕获并限制 PARP 抑制剂的效率。
Cell Rep. 2020 Aug 4;32(5):107985. doi: 10.1016/j.celrep.2020.107985.
6
Synergy between SIRT1 and SIRT6 helps recognize DNA breaks and potentiates the DNA damage response and repair in humans and mice.SIRT1 和 SIRT6 的协同作用有助于识别 DNA 断裂,并增强人类和小鼠的 DNA 损伤反应和修复。
Elife. 2020 Jun 15;9:e55828. doi: 10.7554/eLife.55828.
7
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.FDA 批准概要:阿替利珠单抗联合紫杉醇蛋白结合物用于治疗肿瘤表达 PD-L1 的晚期或转移性三阴性乳腺癌患者。
Clin Cancer Res. 2020 May 15;26(10):2284-2289. doi: 10.1158/1078-0432.CCR-19-3545. Epub 2020 Jan 30.
8
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.卡培他滨联合紫杉醇对比安慰剂联合紫杉醇作为转移性三阴性乳腺癌一线治疗:PAKT 试验。
J Clin Oncol. 2020 Feb 10;38(5):423-433. doi: 10.1200/JCO.19.00368. Epub 2019 Dec 16.
9
Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer.在三阴性乳腺癌中,Smad3水平升高和Smad2水平降低通过TMEPAI/PMEPA1介导转化生长因子-β(TGF-β)从生长抑制因子向生长和转移促进因子的功能转变。
Genes Cancer. 2019;10(5-6):134-149. doi: 10.18632/genesandcancer.194.
10
Targeted Therapies for Triple-Negative Breast Cancer.三阴性乳腺癌的靶向治疗。
Curr Treat Options Oncol. 2019 Nov 21;20(11):82. doi: 10.1007/s11864-019-0682-x.